drugset
drugset / Trial / NCT03970044

Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

NCT03970044 ↗

Phase 4 Completed 67 enrolled Consano Clinical Research, LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase IV, single site, randomized, open-label, parallel study comparing BYDUREON-BCise plus FARXIGA to BYDUREON-BCise alone and FARXIGA alone in patients diagnosed with Type 2 Diabetes Mellitus (T2DM) on a stable dose of metformin alone.

Timeline

Start
2019-07-02
Primary completion
2021-06-01
Completion
2021-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral
Subject Exenatide Peptide 2 mg Other

Indications

type 2 diabetes mellitus